Loading Events

Calliditas In-Person & Virtual R&D Day; The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action

DATE: May 30, 2024
LOCATION: Inderes Event Studio, Västra trädgårdsgatan 19, Stockholm

About The Event

Join Calliditas Therapeutics for an in-person and virtual R&D day featuring Gareth J. Thomas, PhD, FRCPath (University Hospital Southampton) and Jonathan Barratt, PhD, FRCP (University of Leicester) with the following program:

  • Supportive preclinical data and Phase 2 POC trial evaluating setanaxib, the Company’s lead candidate from its NOX platform, in patients with squamous cell carcinoma of the head and neck (SCCHN)
  • The anti-fibrotic effects of Setanaxib in solid tumors and fibrotic diseases
  • Review of upcoming additional clinical data from the NOX platform
  • Support for mode of action of TARPEYO (Nefecon) in patients with primary IgA nephropathy (IgAN)

The event will include a discussion of positive clinical results and supportive pre-clinical and biomarker data recently announced for both programs, as well as an overview of the Company’s pipeline and expected future data readouts.

A live question and answer session will follow the formal presentations.